Gaucher Cells Demonstrate a Distinct Macrophage Phenotype and Resemble Alternatively Activated Macrophages
Open Access
- 1 March 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 122 (3) , 359-369
- https://doi.org/10.1309/bg5v-a8jr-dqh1-m7hn
Abstract
Although the existence of anti-inflammatory alternatively activated macrophages (aamφ) has been accepted widely based on in vitro studies, their in vivo location, phenotype, and function still are debated. Gaucher disease (GD) is caused by a genetic deficiency in the lysosomal enzyme glucocerebrosidase and is characterized by accumulation of glycosphingolipids in so-called Gaucher cells (GCs). By using immunohistochemical analysis, we investigated whether this results in an aamφ phenotype. GCs are macrophage-like cells, expressing acid phosphatase, CD68, CD14, and HLA class II, but not CD11b, CD40, or dendritic cell markers. GCs show infrequent immunoreactivity for mannose receptor. GCs did not express proinflammatory cytokines such as tumor necrosis factor α and monocyte chemoattractant protein 1, but did express the aamφ markers CD163, CCL18, and interleukin-1 receptor antagonist. Furthermore, CD36 and signal receptor protein α, involved in lipid uptake, also were observed on GCs. Thus, GCs represent a distinctive population of myeloid cells that resemble aamφ but differ from previously described in vitro aamφ.Keywords
This publication has 34 references indexed in Scilit:
- 7 Pathological featuresPublished by Elsevier ,2006
- Reciprocal regulation of inflammation and lipid metabolism by liver X receptorsNature Medicine, 2003
- Alternative activation of macrophagesNature Reviews Immunology, 2003
- Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytesTrends in Immunology, 2002
- Anti-inflammatory lipid mediators and insights into the resolution of inflammationNature Reviews Immunology, 2002
- Differential Effects of Enzyme Supplementation Therapy on Manifestations of Type 1 Gaucher DiseaseThe American Journal of Medicine, 1997
- Immunophenotypical comparison of Gaucher's and pseudo‐Gaucher cellsPathology International, 1996
- Individualised low-dose alglucerase therapy for type 1 Gaucher's diseaseThe Lancet, 1995
- Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher diseaseJournal of Inherited Metabolic Disease, 1994
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991